Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
22
Today In Oncology
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo